Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
about
Practical management of patients with chronic myeloid leukemia.Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemiaResponse to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase.The treatment of pediatric chronic myelogenous leukemia in the imatinib eraHow I treat childhood CML.In search of targeted therapies for childhood cancer.Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial EfficiencyEfficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemiaHigher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.Management of chronic myeloid leukemia in childhood.Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signallingLongitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.Myelodysplastic syndrome (MDS)-associated cytogenetic abnormalities in pediatric chronic myelogenous leukemia.Treatment of chronic phase chronic myeloid leukemia with imatinib.Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.Optimal management for pediatric chronic myeloid leukemia.
P2860
Q33849146-C07C5BD2-1BA9-4875-88C9-0703DDCF19B1Q33952848-104B6F21-BEFA-453A-8B04-0FF3BD0EF71AQ34538899-15245125-03CA-421D-B80C-180C03C95389Q35062049-9B5B6095-B92F-4A6B-A7CC-074385806AC9Q35802202-22740BE2-09C1-4D04-A838-73E7E28EE7DAQ35971733-84B822D9-C55D-41D7-85AB-433E8E7EF02BQ36577661-AF23326F-AE8A-40E6-B5C0-EB822D9FE568Q37048013-5AF8ECEA-FCBE-48B6-939F-5BE29D7CE2C8Q37150014-BC5FB272-66BC-4C86-B62D-857EF1B0F59EQ37505017-9061AE24-C2E3-4559-8E68-071715390A01Q37936432-2D23F7F7-4CEA-451B-9E3D-F525D8D84168Q37989418-029C4EDB-8260-4CCD-AA8D-0A8A2BF2671CQ37991223-6E0F4FA6-EC9F-4FC8-B926-7BD4A7875E8FQ39969896-8A743BF2-80BC-4C46-88DB-D015886CA246Q41963473-F213D30D-C1FF-41E9-8E09-72D7DAA83D73Q42662883-52741BCF-F0E7-462D-A75F-ABA7116617C1Q42792947-F5567E41-DF7C-4A49-B934-DAE32E8A0DDBQ43097246-F939F25C-D5A2-4CE4-A1E8-AD0FE7B0DA1FQ44496127-0837FD47-67C3-4115-98AB-8F4B3AE95918Q44774546-9DF99D44-C511-44B1-91D8-2CBFE6E172DEQ49101349-7BFF1093-44A9-425A-93D6-8B211629B9CFQ50548714-12E11CBF-DA18-49CD-917E-BDE1DA090EB5Q51072279-97A4AFE3-FC24-454E-9F9A-DFD60A7E85B7Q52893458-F007387D-E0A0-4566-96C4-EF1838422A46Q55034870-ADA1CFFD-A5B7-42F1-92F3-56DBA9D2C474
P2860
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Imatinib mesylate is effective ...... ter stem cell transplantation.
@en
Imatinib mesylate is effective ...... ter stem cell transplantation.
@nl
type
label
Imatinib mesylate is effective ...... ter stem cell transplantation.
@en
Imatinib mesylate is effective ...... ter stem cell transplantation.
@nl
prefLabel
Imatinib mesylate is effective ...... ter stem cell transplantation.
@en
Imatinib mesylate is effective ...... ter stem cell transplantation.
@nl
P2093
P2860
P356
P1433
P1476
Imatinib mesylate is effective ...... fter stem cell transplantation
@en
P2093
Békassy AN
De Bont ES
Gschaidmeier H
Sufliarska S
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404051
P577
2006-02-01T00:00:00Z